SCYNEXIS (SCYX) Competitors

ADC Therapeutics (NYSE:ADCT) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation.

Which has better valuation and earnings, ADCT or SCYX?

SCYNEXIS has lower revenue, but higher earnings than ADC Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$70.72M	2.21	-$240.05M	-$2.39	-0.68
SCYNEXIS	$3.75M	10.72	$67.04M	-$0.44	-2.34

Which has more volatility & risk, ADCT or SCYX?

ADC Therapeutics has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500.

Do institutionals and insiders believe in ADCT or SCYX?

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 4.1% of ADC Therapeutics shares are held by insiders. Comparatively, 2.9% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media refer more to ADCT or SCYX?

In the previous week, ADC Therapeutics and ADC Therapeutics both had 4 articles in the media. ADC Therapeutics' average media sentiment score of 0.57 beat SCYNEXIS's score of 0.50 indicating that ADC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ADCT or SCYX?

ADC Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 426.32%. Given ADC Therapeutics' higher possible upside, research analysts clearly believe ADC Therapeutics is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
SCYNEXIS	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is ADCT or SCYX more profitable?

ADC Therapeutics has a net margin of -300.00% compared to SCYNEXIS's net margin of -425.41%. ADC Therapeutics' return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-300.00%	N/A	-61.33%
SCYNEXIS	-425.41%	-66.21%	-38.84%

Does the MarketBeat Community prefer ADCT or SCYX?

SCYNEXIS received 445 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 69.85% of users gave SCYNEXIS an outperform vote while only 68.18% of users gave ADC Therapeutics an outperform vote.

Company	Underperform	Outperform
ADC Therapeutics	Outperform Votes 60 68.18%	Underperform Votes 28 31.82%
SCYNEXIS	Outperform Votes 505 69.85%	Underperform Votes 218 30.15%

Summary

ADC Therapeutics and SCYNEXIS tied by winning 8 of the 16 factors compared between the two stocks.